The dynamic interplay between cancer cells and cancer-associated fibroblasts (CAFs) is regulated by multiple signaling pathways, which can lead to cancer progression and therapy resistance. We have previously demonstrated that hMENA, a member of the actin regulatory protein of Ena/VASP family, and its tissue-specific isoforms influence a number of intracellular signaling pathways related to cancer progression. Here, we report a novel function of hMENA/hMENAΔv6 isoforms in tumor-promoting CAFs and in the modulation of pro-tumoral cancer cell/CAF crosstalk via GAS6/AXL axis regulation. LC-MS/MS proteomic analysis reveals that CAFs that overexpress hMENAΔv6 secrete the AXL ligand GAS6, favoring the invasiveness of AXL-expressing pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) cells. Reciprocally, hMENA/hMENAΔv6 regulates AXL expression in tumor cells, thus sustaining GAS6-AXL axis, reported as crucial in EMT, immune evasion, and drug resistance. Clinically, we found that a high hMENA/GAS6/AXL gene expression signature is associated with a poor prognosis in PDAC and NSCLC. We propose that hMENA contributes to cancer progression through paracrine tumor–stroma crosstalk, with far-reaching prognostic and therapeutic implications for NSCLC and PDAC.
The actin modulator hMENA regulates GAS6-AXL axis and pro-tumor cancer/stromal cell cooperation / Melchionna R.; Spada S.; Di Modugno F.; D'Andrea D.; Di Carlo A.; Panetta M.; Mileo A. M.; Sperduti I.; Antoniani B.; Gallo E.; Lawlor R. T.; Piemonti L.; Visca P.; Milella M.; Grazi G. L.; Facciolo F.; Chen E.; Scarpa A.; Nistico P.. - In: EMBO REPORTS. - ISSN 1469-221X. - STAMPA. - 21:(2020), pp. e50078-1-e50078-18. [10.15252/embr.202050078]
The actin modulator hMENA regulates GAS6-AXL axis and pro-tumor cancer/stromal cell cooperation
Grazi G. L.;
2020
Abstract
The dynamic interplay between cancer cells and cancer-associated fibroblasts (CAFs) is regulated by multiple signaling pathways, which can lead to cancer progression and therapy resistance. We have previously demonstrated that hMENA, a member of the actin regulatory protein of Ena/VASP family, and its tissue-specific isoforms influence a number of intracellular signaling pathways related to cancer progression. Here, we report a novel function of hMENA/hMENAΔv6 isoforms in tumor-promoting CAFs and in the modulation of pro-tumoral cancer cell/CAF crosstalk via GAS6/AXL axis regulation. LC-MS/MS proteomic analysis reveals that CAFs that overexpress hMENAΔv6 secrete the AXL ligand GAS6, favoring the invasiveness of AXL-expressing pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) cells. Reciprocally, hMENA/hMENAΔv6 regulates AXL expression in tumor cells, thus sustaining GAS6-AXL axis, reported as crucial in EMT, immune evasion, and drug resistance. Clinically, we found that a high hMENA/GAS6/AXL gene expression signature is associated with a poor prognosis in PDAC and NSCLC. We propose that hMENA contributes to cancer progression through paracrine tumor–stroma crosstalk, with far-reaching prognostic and therapeutic implications for NSCLC and PDAC.File | Dimensione | Formato | |
---|---|---|---|
embr.202050078.pdf
accesso aperto
Licenza:
Open Access
Dimensione
3.27 MB
Formato
Adobe PDF
|
3.27 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.